TMEM44-AS1 promotes esophageal squamous cell carcinoma progression by regulating the IGF2BP2-GPX4 axis in modulating ferroptosis.


Journal

Cell death discovery
ISSN: 2058-7716
Titre abrégé: Cell Death Discov
Pays: United States
ID NLM: 101665035

Informations de publication

Date de publication:
01 Dec 2023
Historique:
received: 28 08 2023
accepted: 16 11 2023
revised: 07 11 2023
medline: 2 12 2023
pubmed: 2 12 2023
entrez: 1 12 2023
Statut: epublish

Résumé

The long non-coding RNA (lncRNA) TMEM44-AS1 is a novel lncRNA whose pro-carcinogenic role in gastric cancer and glioma has been demonstrated. However, its function in esophageal squamous cell carcinoma (ESCC) is unknown. In this study, we identified that TMEM44-AS1 was highly expressed in ESCC tissues and cells. Functionally, TMEM44-AS1 promoted ESCC cell proliferation, invasion and metastasis in vitro and in vivo. TMEM44-AS1 inhibited ferroptosis in ESCC cells, and ferroptosis levels were significantly increased after knockdown of TMEM44-AS1. Mechanistically, TMEM44-AS1 was positively correlated with GPX4 expression, and TMEM44-AS1 could bind to the RNA-binding protein IGF2BP2 to enhance the stability of GPX4 mRNA, thereby affecting ferroptosis and regulating the malignant progression of ESCC. In summary, this study reveals the TMEM44-AS1-IGF2BP2-GPX4 axis could influence cancer progression in ESCC. TMEM44-AS1 can be used as a potential treatment target against ESCC.

Identifiants

pubmed: 38040698
doi: 10.1038/s41420-023-01727-0
pii: 10.1038/s41420-023-01727-0
pmc: PMC10692126
doi:

Types de publication

Journal Article

Langues

eng

Pagination

431

Subventions

Organisme : National Natural Science Foundation of China (National Science Foundation of China)
ID : 82172351
Organisme : National Natural Science Foundation of China (National Science Foundation of China)
ID : 82173018
Organisme : National Natural Science Foundation of China (National Science Foundation of China)
ID : 82002751
Organisme : Natural Science Foundation of Henan Province (Henan Province Natural Science Foundation)
ID : 212300410395

Informations de copyright

© 2023. The Author(s).

Références

Life Sci. 2020 Nov 1;260:118305
pubmed: 32827544
Cell Death Dis. 2021 Apr 6;12(4):349
pubmed: 33824282
J Hematol Oncol. 2019 Mar 29;12(1):34
pubmed: 30925886
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Cell Death Differ. 2016 Mar;23(3):369-79
pubmed: 26794443
World J Gastrointest Oncol. 2014 May 15;6(5):112-20
pubmed: 24834141
Mol Ther. 2021 Jul 7;29(7):2185-2208
pubmed: 33794363
Asian J Surg. 2018 May;41(3):210-215
pubmed: 27986415
Cell Death Dis. 2020 Feb 3;11(2):88
pubmed: 32015325
Nat Cell Biol. 2019 May;21(5):542-551
pubmed: 31048766
Semin Cancer Biol. 2014 Dec;29:3-12
pubmed: 25068994
Int J Mol Sci. 2020 Apr 23;21(8):
pubmed: 32340118
Free Radic Biol Med. 2020 May 20;152:175-185
pubmed: 32165281
Cell Death Dis. 2021 Aug 24;12(9):806
pubmed: 34429400
Nat Commun. 2021 Mar 11;12(1):1589
pubmed: 33707434
Int J Biochem Cell Biol. 2021 Jul;136:106015
pubmed: 34022433
J Exp Clin Cancer Res. 2021 Feb 1;40(1):52
pubmed: 33526059
Nat Rev Cancer. 2021 Jan;21(1):22-36
pubmed: 33082563
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Cell Death Differ. 2022 Sep;29(9):1850-1863
pubmed: 35338333
Cancer Cell Int. 2021 Feb 10;21(1):99
pubmed: 33568150
Gastroenterology. 2018 Jan;154(2):360-373
pubmed: 28823862
Nat Rev Mol Cell Biol. 2021 Apr;22(4):266-282
pubmed: 33495651
Immunol Rev. 2017 May;277(1):150-157
pubmed: 28462529
Oncogene. 2023 Jan;42(2):83-98
pubmed: 36369321
Cell Death Dis. 2022 Nov 18;13(11):967
pubmed: 36400758
Nat Rev Clin Oncol. 2021 May;18(5):280-296
pubmed: 33514910
Cell Death Dis. 2021 Nov 2;12(11):1043
pubmed: 34728613
J Exp Clin Cancer Res. 2021 Oct 25;40(1):337
pubmed: 34696771
Lancet. 2013 Feb 2;381(9864):400-12
pubmed: 23374478
Nat Rev Mol Cell Biol. 2016 Dec;17(12):756-770
pubmed: 27780979
Adv Sci (Weinh). 2022 Aug;9(22):e2105077
pubmed: 35717675
J Hematol Oncol. 2022 May 7;15(1):52
pubmed: 35526050
Cell Death Differ. 2018 Nov;25(11):1980-1995
pubmed: 29511340
Nat Rev Mol Cell Biol. 2021 Feb;22(2):96-118
pubmed: 33353982

Auteurs

Ruotong Yang (R)

Department of Clinical Laboratory, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Key Clinical Laboratory of Henan province, Zhengzhou, China.

Junhu Wan (J)

Department of Clinical Laboratory, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Key Clinical Laboratory of Henan province, Zhengzhou, China.

Liwei Ma (L)

Department of Clinical Laboratory, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Key Clinical Laboratory of Henan province, Zhengzhou, China.

Fuyou Zhou (F)

Thoracic Department, Anyang Tumor Hospital, Henan Key Medical Laboratory of Precise Prevention and Treatment of Esophageal Cancer, Anyang, China.

Zhengwu Yang (Z)

Department of Clinical Laboratory, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Key Clinical Laboratory of Henan province, Zhengzhou, China.

Zhuofang Li (Z)

Department of Clinical Laboratory, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Key Clinical Laboratory of Henan province, Zhengzhou, China.

Mingyuan Zhang (M)

Department of Clinical Laboratory, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Key Clinical Laboratory of Henan province, Zhengzhou, China.

Liang Ming (L)

Department of Clinical Laboratory, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. mingliang@zzu.edu.cn.
Key Clinical Laboratory of Henan province, Zhengzhou, China. mingliang@zzu.edu.cn.

Classifications MeSH